In vitro susceptibility of Clostridium difficile to rifaximin and rifampin in 359 consecutive isolates at a university hospital in Houston, Texas

Journal of Clinical Pathology

Volumn 63, Issue 4, 2010, Pages 355-358

  Jiang, Zhi Dong ^a   DuPont, H L ^a,b,c,d   La Rocco, M ^d   Garey, K W ^d,e  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d ST LUKE S EPISCOPAL HOSPITAL   (United States)

^e UNIVERSITY OF HOUSTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; RIFAMPICIN; RIFAXIMIN;

ADULT; AGAR DILUTION; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATE; CLOSTRIDIUM DIFFICILE; CONTROLLED STUDY; DIARRHEA; FECES ANALYSIS; GENE DELETION; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; UNIVERSITY HOSPITAL;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BACTERIAL TOXINS; CLOSTRIDIUM DIFFICILE; DIARRHEA; ENTEROCOLITIS, PSEUDOMEMBRANOUS; ENTEROTOXINS; GENES, BACTERIAL; HOSPITALS, UNIVERSITY; HUMANS; MICROBIAL SENSITIVITY TESTS; RIFAMPIN; RIFAMYCINS; TEXAS;

EID: 77950393582     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jcp.2009.071688     Document Type: Article

References (35)

1. McFarland LV, Beneda HW, Clarridge JE, et al. Implications of the changing face of Clostridium difficile disease for health care practitioners. Am J Infect Control 2007;35:237-253
2. Muto CA, Pokrywka M, Shutt K, et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005;26:273-280 (Pubitemid 40445086)
3. Pépin J, Valiquette L, Alary M-E, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004;171:466-472
4. Kuijper EJ, Coignard B, Brazier JS, et al. Update of Clostridium difficile-associated disease due to PCR ribotype 027 in Europe. Euro Surveill 2007;12:E1-2.
5. Kuijper EJ, Coignard B, Tüll P, et al. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect 2006; 12(Suppl 6):2-18. (Pubitemid 44362038)
6. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005;353:2442-2449 (Pubitemid 41770165)
7. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005;353:2433-2441 (Pubitemid 41770164)
8. McEllistrem MC, Carman RJ, Gerding DN, et al. A hospital outbreak of Clostridium difficile disease associated with isolates carrying binary toxin genes. Clin Infect Dis 2005;40:265-272
9. Warny M, Pepin J, Fang A, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005;366:1079-1084 (Pubitemid 41338761)
10. Barbut F, Gariazzo B, Bonné L, et al. Clinical features of Clostridium difficile-associated infections and molecular characterization of strains: results of a retrospective study, 2000-2004. Infect Control Hosp Epidemiol 2007;28:131-139
11. Musher DM, Aslam S, Logan N, et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 2005;40:1586-1590 (Pubitemid 40720807)
12. Nair S, Yadav D, Corpuz M, et al. Clostridium difficile colitis: factors influencing treatment failure and relapse - a prospective evaluation. Am J Gastroenterol 1998;93:1873-1876 (Pubitemid 29071697)
13. Pépin J, Alary M-E, Valiquette L, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005;40:1591-1597 (Pubitemid 40720808)
14. Pépin J, Valiquette L, Gagnon S, et al. Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027. Am J Gastroenterol 2007;102:2781-2788 (Pubitemid 350179349)
15. Peláez T, Alcalá L, Alonso R, et al. Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob Agents Chemother 2002;46:1647-1650 (Pubitemid 34535177)
16. Dworczynski A, Sokol B, Meisel-Mikolajczyk F. Antibiotic resistance of Clostridium difficile isolates. Cytobios 1991;65:149-153
17. Marchese A, Salerno A, Pesce A, et al. In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species. Chemotherapy 2000;46:253-266
18. Scarpignato C, Pelosini I. Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy 2005;51:36-66. (Pubitemid 40663190)
19. Vesely JJK, Pien FD, Pien BCT. Rifampin, a useful drug for nonmycobacterial infections. Pharmacotherapy 1998;18:345-357
20. Scarpignato C, Pelosini I. Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic. Digestion 2006;73(Suppl 1):13-27. (Pubitemid 43296214)
21. Hecht DW, Galang MA, Sambol SP, et al. In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother 2007;51:2716-2719
22. Jiang Z-D, DuPont HL, La Rocco M, et al. In vitro activity of rifaximin and rifampin against clinical isolates of Clostridium difficile in Houston, Texas. Anaerobe. Published Online First: 15 Feb 2009. doi:10.1016/j.anaerobe. 2008.12.008.
23. Boero M, Berti E, Morgando A, et al. Treatment for colitis caused by Clostridium difficile: results of a randomized open study of rifaximine vs. vancomycin. Microbiologia Medica 1990;5:74-77
24. Johnson S, Schriever C, Galang M, et al. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis 2007;44:846-848 (Pubitemid 46365312)
25. Garey KW, Jiang Z-D, Bellard A, et al. Rifaximin in treatment of recurrent Clostridium difficile-associated diarrhea: an uncontrolled pilot study [letter]. J Clin Gastroenterol 2009;43:91-92
26. Gumerlock PH, Tang YJ, Meyers FJ, et al. Use of the polymerase chain reaction for the specific and direct detection of Clostridium difficile in human feces. Rev Infect Dis 1991;13:1053-1060
27. Lemée L, Bourgeois I, Ruffin E, et al. Multilocus sequence analysis and comparative evolution of virulence-associated genes and housekeeping genes of Clostridium difficile. Microbiology 2005;151:3171-3180 (Pubitemid 41488902)
28. Stubbs S, Rupnik M, Gibert M, et al. Production of actin-specific ADP-ribosyltransferase (binary toxin) by strains of Clostridium difficile. FEMS Microbiol Lett 2000;186:307-312 (Pubitemid 30232760)
29. Clinical and Laboratory Standards Institute. Methods for antimicrobial susceptibility testing of anaerobic bacteria. Approved standard. 7th edn, Vol 27, No 2. Wayne, PA: Clinical and Laboratory Standards Institute, 2007.
30. th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Chicago, September 17-20, 2007.
31. Curry SR, Marsh JW, Shutt KA, et al. High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital. Clin Infect Dis 2009;48:425-429
32. Artsimovitch I, Vassylyeva MN, Svetlov D, et al. Allosteric modulation of the RNA polymerase catalytic reaction is an essential component of transcription control by rifamycins. Cell 2005;122:351-363 (Pubitemid 41127138)
33. O'Connor JR, Galang MA, Sambol SP, et al. Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile. Antimicrob Agents Chemother 2008;52:2813-2817
34. Barbut F, Decré D, Burghoffer B, et al. Antimicrobial susceptibilities and serogroups of clinical strains of Clostridium difficile isolated in France in 1991 and 1997. Antimicrob Agents Chemother 1999;43:2607-2611
35. Poilane I, Cruaud P, Torlotin JC, et al. Comparison of the E test to the reference agar dilution method for antibiotic susceptibility testing of Clostridium difficile. Clin Microbiol Infect 2000;6:154-156